Early data could give clues about whether gene therapies from Sio, Passage Bio or Lysogene will come out on top in this rare inherited disease.
A focus on rare diseases and regulatory acceptance of cannabis make GW the subject of a $7.2bn buyout.
The US regulator will provide verdicts on cancer projects from TG and Athenex, while Sarepta aims for its third Duchenne approval.
Troriluzole has failed in an Alzheimer’s trial, reminding the markets that this is par for the course in this disease.
Donanemab’s apparent success in a mid-stage trial can be read as support for the beta-amyloid hypothesis, but the reality is more complex.